Summer Sale

50% off Premium Yearly

00days
00hrs
00mins
00secs
NVDA 4.45EWJ 2.89TECK.B.TO 5.26CNQ.TO -0.07HHL.TO 0.035SYLD 1.14HAC.TO 0.14TRU -2.15
Pfizer Inc (PFE)
The ultimate 360° Tracker Your financial life in one place, automatically

NYSE:PFE

Pfizer Inc (PFE)

26.17
+0.57 (2.23%)
as of Jun 11, 2026, 8:00:00 pm Market Open.
322 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
WEAK BUY

Pfizer Inc(PFE)

Jul 22, 2011
Largest drug company in the world. Good pipeline, but they have been paring it down to focus on new drugs. Prefers Teva.
Photo of Richard FoglerRichard Fogler
No
Unlock Rating
$20.07

Stock price when the opinion was issued

$26.17

As of Jun 11, 2026. Market Open.

biotechnologypharmaceutical
BUY ON WEAKNESS

Pfizer Inc(PFE)

Jun 16, 2011
This would be his 2nd choice after Eli Lilly (LLY-N). Facing the issue of a patent cliff where drugs are coming off patent. Has about 4 drugs expecting to move into phase 3 trials. Very attractive multiple. Good dividend yield.
Photo of Mohsin BashirMohsin BashirUnlock Rating
$20.24

Stock price when the opinion was issued

$26.17

As of Jun 11, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

May 12, 2011
Largest global pharma. Likes it. Whole pharma sector has been suffering from a lack of new block buster drugs. This one is facing the expiration of the patent on their Lipitor drug but this is already reflected in the stock price. Have some very promising drugs in phase 2 and 3 clinical trials. Stock is not expensive and has a 4% yield.
Photo of Laura WallaceLaura Wallace
Owned
Unlock Rating
$20.89

Stock price when the opinion was issued

$26.17

As of Jun 11, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Apr 27, 2011
Has done well lately on the potential of it breaking up and selling off the pieces. The difficulty in the whole pharma sector is that it is tough to grow.
Photo of Gordon ReidGordon Reid
No
Unlock Rating
$20.63

Stock price when the opinion was issued

$26.17

As of Jun 11, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Apr 06, 2011
Likes this one especially because they have announced they are going to downsize the company and shareholders will be rewarded for that. Selling a capsule manufacturing company for $2.5 billion.
Photo of Norman LevineNorman LevineUnlock Rating
$20.29

Stock price when the opinion was issued

$26.17

As of Jun 11, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Mar 25, 2011
Drug sector is all suffering from same thing – drugs coming off patent faster than entering the pipeline. Are trying to rebuild themselves. They are all trying to get their costs down.
Photo of Lorne SteinbergLorne SteinbergUnlock Rating
$20.35

Stock price when the opinion was issued

$26.17

As of Jun 11, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Mar 24, 2011
Thinks it is turning around. Very good yield. Have a difficult time with some of the blockbuster drugs coming off patent.
Photo of Paul Harris, CFAPaul Harris, CFAUnlock Rating
$20.30

Stock price when the opinion was issued

$26.17

As of Jun 11, 2026. Market Open.

biotechnologypharmaceutical
COMMENT

Pfizer Inc(PFE)

Mar 15, 2011
Are breaking themselves up after a string of acquisitions. He sees this happening. Want to get rid of their generics.
Photo of Don ReedDon ReedUnlock Rating
$19.76

Stock price when the opinion was issued

$26.17

As of Jun 11, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Feb 28, 2011
New CEO is changing the company compared to the other pharmas. R&D has been a big pit for all companies and he is cutting this back. Will be basically be cutting the company into smaller parts.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$19.24

Stock price when the opinion was issued

$26.17

As of Jun 11, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Feb 11, 2011
Not keen on the big pharma complex at this stage. This one in particular has had struggles with their pipeline. There are better ways to play the health care space.
Photo of Karl BergerKarl BergerUnlock Rating
$18.83

Stock price when the opinion was issued

$26.17

As of Jun 11, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Jan 05, 2011
(A Top Pick Feb 3/10. Down 0.29%.) Model price is $29.91, an upside of 62%. Good dividend. His earnings estimate shows $2.22. Still a Buy.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$18.11

Stock price when the opinion was issued

$26.17

As of Jun 11, 2026. Market Open.

biotechnologypharmaceutical
COMMENT

Pfizer Inc(PFE)

Dec 23, 2010
A lot of the pharmaceuticals have been in the doldrums for a long time. Large dividend yield and cheap on a PE basis but their large blockbuster drugs are coming off patent.
Photo of Paul Harris, CFAPaul Harris, CFA
No
Unlock Rating
$17.61

Stock price when the opinion was issued

$26.17

As of Jun 11, 2026. Market Open.

biotechnologypharmaceutical
WEAK BUY

Pfizer Inc(PFE)

Dec 22, 2010
Coming out of the recession pharmaceuticals have not recovered to 2007 levels. Market worries about Obamacare and generics impact on branded drugs. Also worried about FDA approval process.. Also subject to litigation. Tremendous amount of cash and trading at very low multiples. Looking at this.
Photo of David BaskinDavid Baskin
No
Unlock Rating
$17.56

Stock price when the opinion was issued

$26.17

As of Jun 11, 2026. Market Open.

biotechnologypharmaceutical
COMMENT

Pfizer Inc(PFE)

Dec 17, 2010
Have had a lot of issues and the CEO has left. Has been an abysmal investment over the last 5-10 years. Decent dividend. What do they do when Lipitor goes off patent mid 2011? Their acquisition of Wyeth gives them a decent stream of products. Trading at 8X earnings. Everybody hates it so maybe it’s worth looking at.
Photo of Gavin GrahamGavin GrahamUnlock Rating
$17.03

Stock price when the opinion was issued

$26.17

As of Jun 11, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Dec 16, 2010
Looked at it a couple of times. Lots of cash, good name, but he has never been able to pull the trigger. He thinks you need to let it go up a bit and increase volume, but if you own it, you get paid to wait.
Photo of Rick StuchberryRick StuchberryUnlock Rating
$17.22

Stock price when the opinion was issued

$26.17

As of Jun 11, 2026. Market Open.

biotechnologypharmaceutical
Showing 346 to 360 of 801 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

VEEV -2.21$161.55
WSP.TO 0.31$183.77
VRTX 9.33$445.04
OTEX.TO 0.24$30.52
CCO.TO 5.6$138.04

Today's Top Picks

NVDA 4.45$204.87
EWJ 2.89$92.18
TECK.B.T… 5.26$88.81
CNQ.TO -0.07$63.52
HHL.TO 0.035$6.945

Popular Articles

Latest Sell Signals

TD.TO 2.57$162.22
MBLY 0.44$9.58
ASAN -0.12$7.46
MODG 0.53$16.79
NVTS 1.71$22.21

Most Recent Experts

Stockchase Insights

Stockchase Insights

5i Research

Brian Acker, CA

Brian Acker, CA

Acker Finley Inc.

The Weekly Buzzing Stocks by Billy Kawasaki

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

David Burrows

David Burrows

Barometer Capital Management

Jim Cramer - Mad Money

Jim Cramer - Mad Money

CNBC

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica